ZURA vs. GHRS, TRML, MLYS, ARCT, CDXC, AKBA, ANNX, SIGA, MREO, and KROS
Should you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include GH Research (GHRS), Tourmaline Bio (TRML), Mineralys Therapeutics (MLYS), Arcturus Therapeutics (ARCT), ChromaDex (CDXC), Akebia Therapeutics (AKBA), Annexon (ANNX), SIGA Technologies (SIGA), Mereo BioPharma Group (MREO), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical products" industry.
Zura Bio vs.
GH Research (NASDAQ:GHRS) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability, community ranking and analyst recommendations.
GH Research currently has a consensus target price of $35.67, indicating a potential upside of 268.08%. Zura Bio has a consensus target price of $15.80, indicating a potential upside of 797.73%. Given Zura Bio's higher probable upside, analysts clearly believe Zura Bio is more favorable than GH Research.
GH Research's return on equity of -20.29% beat Zura Bio's return on equity.
In the previous week, GH Research had 12 more articles in the media than Zura Bio. MarketBeat recorded 16 mentions for GH Research and 4 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.87 beat GH Research's score of 0.52 indicating that Zura Bio is being referred to more favorably in the news media.
GH Research received 7 more outperform votes than Zura Bio when rated by MarketBeat users. However, 79.17% of users gave Zura Bio an outperform vote while only 74.29% of users gave GH Research an outperform vote.
56.9% of GH Research shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 41.6% of GH Research shares are owned by insiders. Comparatively, 22.1% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
GH Research has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.
Summary
GH Research beats Zura Bio on 7 of the 13 factors compared between the two stocks.
Get Zura Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zura Bio Competitors List
Related Companies and Tools
This page (NASDAQ:ZURA) was last updated on 1/31/2025 by MarketBeat.com Staff
Free ZURA Stock Alerts